Baidu
map

NPJ Vaccines:重磅!可以根治牛皮癣的疫苗已经进入人体试验阶段

2017-10-23 Lily 来宝网

邓迪大学和牛津大学的研究表明,如何结合破伤风疫苗的病毒粒子治疗牛皮癣和过敏,甚至还可能预防阿尔茨海默氏症。

接种疫苗对牛皮癣、过敏和阿尔茨海默氏症的可能性】邓迪大学和牛津大学的研究表明,如何结合破伤风疫苗的病毒粒子治疗牛皮癣和过敏,甚至还可能预防阿尔茨海默氏症

以邓迪大学博士为首的科学家们和牛津大学的研究人员使用已知的破伤风疫苗推导出已知蛋白质结构,可以刺激免疫系统,对预防和治疗多种慢性疾病提高了可能性。

不仅对牛皮癣和过敏显示出积极的作用,还有益与预防阿尔茨海默氏症。研究人员表示:“皮肤科医生对免疫系统有特殊兴趣,而且我特别关注对慢性皮肤疾病疫苗的开发。这个想法很简单,就是希望找到应对牛皮癣、湿疹等疾病的方法,目前,最新和最有效的药物就是所谓的“抗体”,为慢性疾病设计的抗体是特别针对人体自身蛋白质的。通过阻断一个蛋白质,这种疾病就会好转。牛皮癣使用的是一种叫做白介素17的蛋白质,通过创建疫苗刺激人体产生抗体,延缓疾病的发展。

“我们的研究表明,这种技术在小鼠体内表现良好,重要的是,我们的新疫苗技术表明,这种疫苗对老年人更加有益。”研究结果发表于《疫苗》杂志中。研究人员现在已经开始进行临床试验,并且已经获批对人类进行测试。目前治疗牛皮癣的抗体通常注射一次可以维持一个月,每年的成本约£10000,此次疫苗的成本大有改进,可以让更多的人负担得起。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-09-18 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-25 xxxx1054
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-25 jeanqiuqiu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 阿杜12138

    查查这个杂志

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1773668, encodeId=d95f1e7366804, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Sep 18 03:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321070, encodeId=99f313210e09f, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325572, encodeId=190a13255e2d3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513631, encodeId=4fb11513631ff, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24703, encryptionId=c41924e0391, topicName=人体试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ab10580029, createdName=ms5906905816781247, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549212, encodeId=52d9154921285, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586074, encodeId=e5a515860e49f, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Oct 25 12:40:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255453, encodeId=ab4d255453c0, content=查查这个杂志, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/10/16d33b9abecd6440b30b37e6ad8db1a6.jpg, createdBy=f6f72168266, createdName=阿杜12138, createdTime=Mon Oct 23 22:29:19 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255440, encodeId=fe34255440a0, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:58 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Sci Trans Med:研究发现治疗牛皮癣的安全、有效新靶点!

伦敦国王学院的科学家发现,已知在牛皮癣发展中发挥重要作用的蛋白质功能可以被抑制,而不会对患者造成风险。

J Invest Dermatol:揭示牛皮癣和寿命长短的关系

身体越多表面出现牛皮癣,患者遭受死亡的风险就越大,这是来自宾夕法尼亚大学佩雷尔曼医学院研究人员们的一项最新研究结果,这项研究发表在《皮肤病学研究》杂志上,是第一次将牛皮癣严重程度与死亡风险进行链接的研究,此处所说的严重程度指的是,牛皮癣在身体表面的覆盖程度,而不是治疗程度。

Oncotarget:1w+病例分析汉族人群中的牛皮癣特征

牛皮癣是一种常见的具有特征性皮损的慢性易于复发的炎症性皮肤病。初起为炎性红色丘疹,约粟粒至绿豆大小,以后逐渐扩大或融合成为棕红色斑块,边界清楚,周围有炎性红晕,基底浸润明显,表面覆盖多层干燥的灰白色或银白色鳞屑。

Lancet:生物制剂tildrakizumab:牛皮癣“克星”,治疗效果超神奇!

慢性斑块性银屑病的症状为皮肤上出现红色的斑块,头皮,手肘和膝盖出现鳞状皮肤。慢性斑块性银屑病通常出现在青春期或中年,需要终生服药。1990年代之前,医生对重度牛皮癣患者几乎束手无策,多达四分之一的牛皮癣患者症状发展到全身皮肤的10到100%不等。

J Clin Inves:胆固醇高与牛皮癣有关系?

一项西北医学发表在《临床研究杂志》的研究已经证明,一类特殊的免疫细胞在高胆固醇与牛皮癣症状之间有一个之前所未知的联系。

BRIT J DERMATOL:研究确定生物疗法对牛皮癣的长久效果!

生物治疗牛皮癣在临床试验中取得了良好的效果,因为大多数的分析都集中在单一生物制剂的短期结果,人们对临床实践的长期结果一直知之甚少,因此不断切换生物制剂是常见的。近期,发表于《英国皮肤病》杂志上的文章中,报道了来自瑞典研究人员们长达10年的研究,此次试验参与者共计583人,试验显示了生物制剂的长期有效性。

Baidu
map
Baidu
map
Baidu
map